Global Innovative Platforms (GIPL) Liabilities and Shareholders Equity (2021 - 2026)
Global Innovative Platforms' (GIPL) quarterly Liabilities and Shareholders Equity came in at $539261.0 in Q2 2026, up 157.82% year-over-year from $209160.0 in Q2 2025, and down 8.9% quarter-over-quarter from $591958.0 in Q1 2026.
Powered by 
Analysis
Global Innovative Platforms (GIPL) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Global Innovative Platforms has disclosed Liabilities and Shareholders Equity across 6 years of filings, most recently posting $539261.0 for Q2 2026.
- In Q2 2026, Liabilities and Shareholders Equity rose 157.82% year-over-year to $539261.0; the TTM figure through Jun 2026 stood at $1.6 million (up 196.52% YoY), while the FY2025 annual figure was $199275.0, up 1328400.0% from the prior year.
- Liabilities and Shareholders Equity came in at $539261.0 for Q2 2026 at Global Innovative Platforms, down from $591958.0 in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $591958.0 in Q1 2026 to a low of $15.0 in Q3 2024.
- Average Liabilities and Shareholders Equity over 5 years is $122714.4, with a median of $28951.5 recorded in 2022.
- Year-over-year, Liabilities and Shareholders Equity plunged 99.13% in 2023 and surged 1328400.0% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $64403.0 in 2022, then plunged by 97.38% to $1685.0 in 2023, then surged by 8710.62% to $148459.0 in 2024, then surged by 51.52% to $224951.0 in 2025, then surged by 139.72% to $539261.0 in 2026.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $539261.0 in Q2 2026, $591958.0 in Q1 2026, and $224951.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.57 Bn | 40.38 Bn | 779.09 Mn | 3.44 Bn |
| 2 | Zoetis | 30.57 Bn | 28.90 Bn | 1.05 Bn | 15.08 Bn |
| 3 | Elanco Animal Health | 11.47 Bn | 10.94 Bn | 798.00 Mn | 13.56 Bn |
| 4 | Phibro Animal Health | 1.43 Bn | 1.35 Bn | 134.40 Mn | 1.50 Bn |
| 5 | Immucell | 87.38 Mn | 78.52 Mn | 2.44 Mn | 46.63 Mn |
| 6 | Zhengye Biotechnology Holding | 64.40 Mn | 57.30 Mn | - | 61.54 Mn |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | 539,261.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 539,261.00 |
| Mar 31, 2026 | 591,958.00 |
| Dec 31, 2025 | 224,951.00 |
| Sep 30, 2025 | 199,275.00 |
| Jun 30, 2025 | 209,160.00 |
| Mar 31, 2025 | 166,932.00 |
| Dec 31, 2024 | 148,459.00 |
| Sep 30, 2024 | 15.00 |
| Jun 30, 2024 | 10,146.00 |
| Mar 31, 2024 | 596.00 |
| Dec 31, 2023 | 1,685.00 |
| Sep 30, 2023 | 415.00 |
| Jun 30, 2023 | 361.00 |
| Mar 31, 2023 | 2,961.00 |
| Dec 31, 2022 | 64,403.00 |
| Sep 30, 2022 | 47,757.00 |
| Jun 30, 2022 | 262.00 |
| Mar 31, 2022 | 262.00 |
| Dec 31, 2021 | 262.00 |
| Sep 30, 2021 | 262.00 |